IRIS Accounts Production v25.4.0.155 12152114 Board of Directors 1.1.24 31.12.24 31.12.24 Medium entities true true false true true false false true false These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh121521142023-12-31121521142024-12-31121521142024-01-012024-12-31121521142022-12-31121521142023-01-012023-12-31121521142023-12-3112152114ns15:EnglandWales2024-01-012024-12-3112152114ns14:PoundSterling2024-01-012024-12-3112152114ns10:Director12024-01-012024-12-3112152114ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3112152114ns10:MediumEntities2024-01-012024-12-3112152114ns10:Audited2024-01-012024-12-3112152114ns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-01-012024-12-3112152114ns10:Medium-sizedCompaniesRegimeForAccounts2024-01-012024-12-3112152114ns10:FullAccounts2024-01-012024-12-3112152114ns10:OrdinaryShareClass12024-01-012024-12-3112152114ns10:Director22024-01-012024-12-3112152114ns10:RegisteredOffice2024-01-012024-12-3112152114ns5:CurrentFinancialInstruments2024-12-3112152114ns5:CurrentFinancialInstruments2023-12-3112152114ns5:Non-currentFinancialInstruments2024-12-3112152114ns5:Non-currentFinancialInstruments2023-12-3112152114ns5:ShareCapital2024-12-3112152114ns5:ShareCapital2023-12-3112152114ns5:RetainedEarningsAccumulatedLosses2024-12-3112152114ns5:RetainedEarningsAccumulatedLosses2023-12-3112152114ns5:ShareCapital2022-12-3112152114ns5:RetainedEarningsAccumulatedLosses2022-12-3112152114ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-3112152114ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-311215211412024-01-012024-12-311215211422024-01-012024-12-311215211422023-01-012023-12-311215211452024-01-012024-12-311215211452023-01-012023-12-3112152114ns5:CostValuation2023-12-3112152114ns5:Subsidiary12024-01-012024-12-31121521141ns5:Subsidiary12024-01-012024-12-3112152114ns5:Subsidiary22024-01-012024-12-3112152114ns5:Subsidiary232024-01-012024-12-3112152114ns5:Subsidiary32024-01-012024-12-31121521145ns5:Subsidiary32024-01-012024-12-3112152114ns5:Subsidiary42024-01-012024-12-31121521147ns5:Subsidiary42024-01-012024-12-3112152114ns5:Subsidiary52024-01-012024-12-3112152114ns5:Subsidiary592024-01-012024-12-3112152114ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3112152114ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3112152114ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2023-12-3112152114ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2024-12-3112152114ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-12-3112152114ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2023-12-3112152114ns10:OrdinaryShareClass12024-12-3112152114ns5:RetainedEarningsAccumulatedLosses2023-12-31
REGISTERED NUMBER: 12152114 (England and Wales)















Strategic Report, Report of the Directors and

Audited Financial Statements for the Year Ended 31 December 2024

for

Access Fertility Bidco Limited

Access Fertility Bidco Limited (Registered number: 12152114)






Contents of the Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Strategic Report 2

Report of the Directors 4

Report of the Independent Auditors 6

Income Statement 10

Other Comprehensive Income 11

Balance Sheet 12

Statement of Changes in Equity 13

Notes to the Financial Statements 14


Access Fertility Bidco Limited

Company Information
for the Year Ended 31 December 2024







DIRECTORS: R N Quijano
A C Miller





REGISTERED OFFICE: Carlton House
High Street
Higham Ferrers
Northamptonshire
NN10 8BW





REGISTERED NUMBER: 12152114 (England and Wales)





AUDITORS: Willsons (Higham Ferrers) Ltd
Chartered Accountants
Statutory Auditors
Carlton House
High Street
Higham Ferrers
Northamptonshire
NN10 8BW

Access Fertility Bidco Limited (Registered number: 12152114)

Strategic Report
for the Year Ended 31 December 2024

The directors present their strategic report for the year ended 31 December 2024.

REVIEW OF BUSINESS
Access Fertility Bidco Limited started on 17 October 2019 by acquiring Access Fertility Limited, Access Fertility Building Limited, Access Fertility International Limited and Access Fertility Ireland Limited. Incorporated companies, Access Fertility Poland Limited, Access Fertility Greece Limited and Access Fertility Spain Limited, have subsequently been added to the group under Access Fertility International Limited. A newly incorporated company Access Fertility Espana SL was formed under Access Fertility Bidco Limited.

The Redia Group was acquired in 2023 also under Access Fertility Bidco Limited.

The company's Key Performance Indicators ('KPI's') were profit after interest and tax and the return on its investment.

The company loss after interest and tax for the period was £3,007,027 (2023 - £2,875,337). Please refer to the income statement for results.

The company continues to be in a net current liability and also a net liability position.

The group has undertaken significant long and medium-term investments to try to gain entry into new geographic markets, improving the delivery of services, and the launch of new products. However this level of investment has resulted in forecast short term losses in the main trading subsidiary and also a significant investment of working capital. This trading loss further reduces the ability of the group to reduce the debt burden and therefore increases long term interest and reliance on the support of the senior lender.

The group has taken the decision to reduce some of the trading costs focussed on new geographic markets to improve its core trading results.

The group still has a positive bank balance and the underlying group trading business is forecast to return to profitability and through the continued support of the senior lender, stronger clinic partnerships and improvement to patient programme offerings, the patient enrolments continue to grow year on year enabling the core trading results to continue to improve. Further, following the new financing agreement which converts significant debt to equity and substantially reduces the overall debt burden, the senior lender has agreed that interest charges on the remaining facilities will not be called in for payment for at least 12 months, (this is further discussed in the going concern section of this report).

The group made the decision last year end to sell the freehold office building as these were not being utilised and this sale was completed in July 2024.


Access Fertility Bidco Limited (Registered number: 12152114)

Strategic Report
for the Year Ended 31 December 2024

PRINCIPAL RISKS AND UNCERTAINTIES
The company has loan agreements and covenant requirements with lenders. A principal risk is the company not receiving sufficient dividends from the underlying trading group in order to make interest payments to the lender. Therefore, the Company's main concerns are attributable to the sound operation of the underlying trading group, ensuring that profit and cash flows are maintained to meet the terms of the lending agreements.

Therefore the company has exposure to liquidity and cash flow risks due to the demands placed on it to meet interest repayments. Increase in the rates of applicable interest could therefore adversely impact the cash flows of the group.

As with any group there is a risk of general or specific adverse trading conditions, including the risk to the business that the market does not grow in line with our projections, competition and that economic growth is below expectations.

We aim to minimise those risks by continuing to improve our differentiated offerings via quality and value of service and innovation. The belief in the future is strong and strengthen by the success of our recent product launches.

The company regularly reviews its trading results and updates its forecast to ensure it has sufficient headroom within its secured facilities to accommodate reasonable fluctuations in results.

ON BEHALF OF THE BOARD:





A C Miller - Director


18 December 2025

Access Fertility Bidco Limited (Registered number: 12152114)

Report of the Directors
for the Year Ended 31 December 2024

The directors present their report with the financial statements of the company for the year ended 31 December 2024.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of a holding company.

DIVIDENDS
No dividends will be distributed for the year ended 31 December 2024.

FUTURE DEVELOPMENTS
See Going Concern note.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 January 2024 to the date of this report.

R N Quijano
A C Miller

GOING CONCERN
The company's business activities, together with the factors likely to affect its future development, performance and position are set out in the Business Review and Principal Risks and Uncertainties in the Strategic Report.

Whilst the directors have instituted long term measures to grow patient enrolment numbers, the significant investments discussed in the Strategic Report reduced trading results and cash flows during 2024.

Post year-end, in early 2025, the group took positive action to reduce trading costs in order to improve its core trading results.

The directors also made the decision to sell a freehold property that was not being utilised since the pandemic to provide additional financial headroom during this time of investment and the sale of this property was completed in July 2024.

In addition, subsequent to the year-end, a new financing agreement was signed with Beechbrook Capital LLP (the controlling shareholder) which converts a significant level of debt to equity and greatly reduces the interest burden on the business. This agreement demonstrates Beechbrook's continued commitment to supporting the group's growth strategy.

The group has a significant positive bank balance, and the underlying trading business has continued to strengthen post year-end (fuelled by growth in enrolments). Through the continued support of the senior lender, strong clinic partnerships and improvement to patient programme offerings, the patient enrolment numbers continue to grow, enabling the core trading results to improve.

The directors, having assessed the responses of the senior lender to the directors enquiries relating to the covenants, the level of debt in the business, and the senior lenders ongoing support (which is based on their continuing positive expectation of a profitable future for the business), have no reason to believe that a material uncertainty exists that may cast significant doubt about the ability of the group or company to continue as a going concern.

The group and trading company's forecasts and projections taking account of possible fluctuations in trading performance show that the company will be able to operate within the level of its current resources, notwithstanding the net liabilities.

On the basis of their assessment of the group's financial position, enquiries made of the senior lender and future financial plans, the company's directors expect that the company will be able to continue in operational existence for at least 12 months from the approval of these financial statements. Thus, they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

DISCLOSURE IN THE STRATEGIC REPORT
The Review of Business and Principal Risks and Uncertainties have been disclosed in the strategic report.


Access Fertility Bidco Limited (Registered number: 12152114)

Report of the Directors
for the Year Ended 31 December 2024

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

AUDITORS
The auditors, Willsons (Higham Ferrers) Ltd, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





A C Miller - Director


18 December 2025

Report of the Independent Auditors to the Members of
Access Fertility Bidco Limited

Opinion
We have audited the financial statements of Access Fertility Bidco Limited (the 'company') for the year ended 31 December 2024 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its loss for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
Access Fertility Bidco Limited


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page five, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
Access Fertility Bidco Limited


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

We obtained an understanding of the legal and regulatory framework that the Company operates in, and identified the key laws and regulations.

We considered the key laws and regulations that have a direct impact on the financial statements are the reporting framework, the relevant tax legislation and Companies Act 2006.

We also considered the laws and regulations that have an indirect impact on the financial statement where the consequences of non-compliance could have a material effect on amounts or disclosures due to the imposition of fines.

Audit procedure performed by the engagement team included:
- Enquiry of management, those charged with governance around actual and potential litigation and claims;
- Enquiry of management in compliance functions to identify any instances of non-compliance with laws and regulations;
- Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.
- Performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of
Access Fertility Bidco Limited


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Craig Baird FCA (Senior Statutory Auditor)
for and on behalf of Willsons (Higham Ferrers) Ltd
Chartered Accountants
Statutory Auditors
Carlton House
High Street
Higham Ferrers
Northamptonshire
NN10 8BW

19 December 2025

Access Fertility Bidco Limited (Registered number: 12152114)

Income Statement
for the Year Ended 31 December 2024

31.12.24 31.12.23
Notes £    £   

TURNOVER - -

Administrative expenses 145,352 121,094
OPERATING LOSS 4 (145,352 ) (121,094 )


Interest payable and similar expenses 5 2,861,675 2,754,243
LOSS BEFORE TAXATION (3,007,027 ) (2,875,337 )

Tax on loss 6 - -
LOSS FOR THE FINANCIAL YEAR (3,007,027 ) (2,875,337 )

Access Fertility Bidco Limited (Registered number: 12152114)

Other Comprehensive Income
for the Year Ended 31 December 2024

31.12.24 31.12.23
Notes £    £   

LOSS FOR THE YEAR (3,007,027 ) (2,875,337 )


OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME FOR
THE YEAR

(3,007,027

)

(2,875,337

)

Access Fertility Bidco Limited (Registered number: 12152114)

Balance Sheet
31 December 2024

31.12.24 31.12.23
Notes £    £    £    £   
FIXED ASSETS
Investments 7 15,763,294 15,763,294

CURRENT ASSETS
Debtors 8 2,078 26,391
Cash at bank 304 301
2,382 26,692
CREDITORS
Amounts falling due within one year 9 15,077,074 13,295,036
NET CURRENT LIABILITIES (15,074,692 ) (13,268,344 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

688,602

2,494,950

CREDITORS
Amounts falling due after more than one year 10 19,109,165 17,908,486
NET LIABILITIES (18,420,563 ) (15,413,536 )

CAPITAL AND RESERVES
Called up share capital 14 1 1
Retained earnings 15 (18,420,564 ) (15,413,537 )
SHAREHOLDERS' FUNDS (18,420,563 ) (15,413,536 )

The financial statements were approved by the Board of Directors and authorised for issue on 18 December 2025 and were signed on its behalf by:





A C Miller - Director


Access Fertility Bidco Limited (Registered number: 12152114)

Statement of Changes in Equity
for the Year Ended 31 December 2024

Called up
share Retained Total
capital earnings equity
£    £    £   
Balance at 1 January 2023 1 (12,538,200 ) (12,538,199 )

Changes in equity
Total comprehensive income - (2,875,337 ) (2,875,337 )
Balance at 31 December 2023 1 (15,413,537 ) (15,413,536 )

Changes in equity
Total comprehensive income - (3,007,027 ) (3,007,027 )
Balance at 31 December 2024 1 (18,420,564 ) (18,420,563 )

Access Fertility Bidco Limited (Registered number: 12152114)

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

Access Fertility Bidco Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Financial Reporting Standard 102 - reduced disclosure exemptions
The company has taken advantage of the following disclosure exemption in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

the requirements of Section 7 Statement of Cash Flows.

Preparation of consolidated financial statements
The financial statements contain information about Access Fertility Bidco Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 400 of the Companies Act 2006 from the requirements to prepare consolidated financial statements as it and its subsidiary undertaking are included by full consolidation in the consolidated financial statements of its parent, Access Fertility Topco Limited, Carlton House, High Street, Higham Ferrers, Nothamptonshire NN10 8BW.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Access Fertility Bidco Limited (Registered number: 12152114)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Critical accounting judgements and key sources of estimation uncertainty
Judgements made by the Directors, in the application of these accounting policies that have significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year are discussed below.

The preparation of financial statements management are required to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based upon historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgements about carrying values of assets and liabilities that are not readily available from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only the period or in the period of revision and future periods if the revision affects both current and future periods.

Management consider the following to be a significant accounting policy or a key source of estimation uncertainty for the preparation of the financial statements:

Going concern
The company's business activities, together with the factors likely to affect its future development, performance and position are set out in the Business Review and Principal Risks and Uncertainties in the Strategic Report.

Whilst the directors have instituted long term measures to grow patient enrolment numbers, the significant investments discussed in the Strategic Report reduced trading results and cash flows during 2024.

Post year-end, in early 2025, the group took positive action to reduce trading costs in order to improve its core trading results.

The directors also made the decision to sell a freehold property that was not being utilised since the pandemic to provide additional financial headroom during this time of investment and the sale of this property was completed in July 2024.

In addition, subsequent to the year-end, a new financing agreement was signed with Beechbrook Capital LLP (the controlling shareholder) which converts a significant level of debt to equity and greatly reduces the interest burden on the business. This agreement demonstrates Beechbrook's continued commitment to supporting the group's growth strategy.

The group has a significant positive bank balance, and the underlying trading business has continued to strengthen post year-end (fuelled by growth in enrolments). Through the continued support of the senior lender, strong clinic partnerships and improvement to patient programme offerings, the patient enrolment numbers continue to grow, enabling the core trading results to improve.

The directors, having assessed the responses of the senior lender to the directors enquiries relating to the covenants, the level of debt in the business, and the senior lenders ongoing support (which is based on their continuing positive expectation of a profitable future for the business), have no reason to believe that a material uncertainty exists that may cast significant doubt about the ability of the group or company to continue as a going concern.

The group and trading company's forecasts and projections taking account of possible fluctuations in trading performance show that the company will be able to operate within the level of its current resources, notwithstanding the net liabilities.

On the basis of their assessment of the group's financial position, enquiries made of the senior lender and future financial plans, the company's directors expect that the company will be able to continue in operational existence for at least 12 months from the approval of these financial statements. Thus, they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

Investment impairment
The company recognised an impairment loss to investment cost of £11,589,709 in 2021. The adjustment to the estimated recoverable amount was based on the higher value of the fair value of the cash-generating unit, the shares in the group's trading subsidiaries.


Access Fertility Bidco Limited (Registered number: 12152114)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued
The directors consider that no further impairment is required this year as the main subsidiary's cash generating activity remains consistent, it is only the additional investment into new activities that has created the forecast short term losses.

The directors acknowledge that as with all estimation this contains a degree of estimation uncertainty that has a risk of causing a material adjustment to the carrying amounts of assets.

Investments in subsidiaries
Investments in subsidiaries and associates are recognised at cost less impairment in the individual financial statements.

Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the assets and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

Financial instruments
Basic debt instruments such as loans are initially recognised at the transaction price including transaction costs. Subsequently, they are generally measured at amortised cost using the effective interest rate method, less impairment or an approximation of such a method. The effective interest method aims to allocate the interest over the life of an instrument at a constant rate, based on its carrying amount.

On market rate loans the financial liability is basically recognised initially at an amount equal to the principal payable at maturity. As such on variable rate loans there will be no need to re-estimate the future interest payments as this would normally have no significant effect on the carrying amount of the liability.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Debtors and creditors within one year
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at
transaction price. Any losses arising from impairment are recognised in the profit and loss account in other
administrative expenses.

Access Fertility Bidco Limited (Registered number: 12152114)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

3. EMPLOYEES AND DIRECTORS
31.12.24 31.12.23
£    £   
Wages and salaries 105,639 106,381
Social security costs 9,095 9,095
114,734 115,476

The average number of employees during the year was as follows:
31.12.24 31.12.23

Director 1 1
Chairman 1 1
2 2

31.12.24 31.12.23
£    £   
Directors' remuneration 30,639 31,381

4. OPERATING LOSS

The operating loss is stated after charging/(crediting):

31.12.24 31.12.23
£    £   
Auditors' remuneration 6,318 2,333
Foreign exchange differences (283 ) -

5. INTEREST PAYABLE AND SIMILAR EXPENSES
31.12.24 31.12.23
£    £   
Loan arrangement fees 99,141 123,656
Loan interest 2,412,402 2,297,766
Vendor loan interest 350,132 332,821
2,861,675 2,754,243

6. TAXATION

Analysis of the tax charge
No liability to UK corporation tax arose for the year ended 31 December 2024 nor for the year ended 31 December 2023.

Access Fertility Bidco Limited (Registered number: 12152114)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

6. TAXATION - continued

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

31.12.24 31.12.23
£    £   
Loss before tax (3,007,027 ) (2,875,337 )
Loss multiplied by the standard rate of corporation tax in the UK of 25% (2023 -
25%)

(751,757

)

(718,834

)

Effects of:
Expenses not deductible for tax purposes 25,514 21,004
Group relief 38,247 32,756
Tax asset not recognised 687,996 665,074

Total tax charge - -

7. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 January 2024
and 31 December 2024 15,763,294
NET BOOK VALUE
At 31 December 2024 15,763,294
At 31 December 2023 15,763,294

The company's investments at the Balance Sheet date in the share capital of companies include the following:

Access Fertility Limited
Registered office: Carlton House, High Street, Higham Ferrers, Northants,NN10 8BW
Nature of business: IVF programmes
%
Class of shares: holding
Ordinary 100.00

Access Fertility International Limited
Registered office: Carlton House, High Street, Higham Ferrers, Northants,NN10 8BW
Nature of business: IVF programmes
%
Class of shares: holding
Ordinary 100.00

Access Fertility Bidco Limited (Registered number: 12152114)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

7. FIXED ASSET INVESTMENTS - continued

Your Fertility Ltd
Registered office: Carlton House, High Street, Higham Ferrers, Northants,NN10 8BW
Nature of business: IVF programmes
%
Class of shares: holding
Ordinary 100.00

The company was incorporated on 31 January 2023 and is dormant during year.

Redia Ltd
Registered office: Carlton House, High Street, Higham Ferrers, Northants,NN10 8BW
Nature of business: IVF programmes
%
Class of shares: holding
Ordinary 100.00

The company acquired Redia Ltd and its subsidiaries for £250,000 plus legal fees of £10,719 on 28 June 2023.

Access Fertility Espana SL
Registered office: Carlton House, High Street, Higham Ferrers, Northants,NN10 8BW
Nature of business: IVF programmes
%
Class of shares: holding
Ordinary 100.00

Access Fertility Espana SL was incorporated in Spain on 16 June 2023 with share capital of Euro 3,000 (£2,574).

8. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 31.12.23
£    £   
Amounts owed by group undertakings - 20,636
Prepayments 2,078 5,755
2,078 26,391

9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 31.12.23
£    £   
Other loans (see note 11) 90,592 100,000
Amounts owed to group undertakings 14,931,230 13,139,568
VAT 2,089 2,594
Unpaid share investments 48,251 48,251
Accrued expenses 4,912 4,623
15,077,074 13,295,036

10. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
31.12.24 31.12.23
£    £   
Other loans (see note 11) 18,459,949 17,763,736
Unpaid share investments 96,500 144,750
Accrued Beecbbrook interest 552,716 -
19,109,165 17,908,486

Access Fertility Bidco Limited (Registered number: 12152114)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

11. LOANS

An analysis of the maturity of loans is given below:

31.12.24 31.12.23
£    £   
Amounts falling due within one year or on demand:
Vendor loans 90,592 100,000

Amounts falling due between one and two years:
Vendor loans 4,593,726 96,930
Beechbrook loan 13,866,223 -
18,459,949 96,930

Amounts falling due between two and five years:
Vendor loans - 4,211,656
Beechbrook loan - 13,455,150
- 17,666,806

12. SECURED DEBTS

The following secured debts are included within creditors:

31.12.24 31.12.23
£    £   
Beechbrook loan 13,866,223 13,455,150

The loan is secured on fixed and floating charge on all the property or undertaking of the company.

Access Fertility Bidco Limited (Registered number: 12152114)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

13. FINANCIAL INSTRUMENTS

There are two Beechbrook loan facilities. Facility A is for £9,000,000 and Facility B is for £2,300,000. The agreement was originally entered into on 17 October 2019, both loans were repayable five years after first utilised or 16 October 2024. The amendment and restatement deed were entered into on 22 March 2023 and the termination date is extended to 1 December 2026.

Before the amendment and restatement deed, Facility A's annual interest rate is variable by option. If the interest is part paid cash and part capitalised, the cash paid element is at 5% + LIBOR and the capitalised element is at 7%. If the interest is fully paid cash then the rate is 11.5% + LIBOR. After the amendment and restatement deed, the interest is fully paid cash and the rate is 11.5% + LIBOR.

Before the amendment and restatement deed, Facility B's annual interest rate is capitalised at a rate of 15% + LIBOR until redemption. After the amendment and restatement deed, the interest is part paid cash and part capitalised, the cash paid element is at 10% + LIBOR and the capitalised element is at 5%.

The total balance at the year-end including capitalised interest, but excluding arrangement fees was £13,866,223 (2023 - £13,550,691). The balance of the loan arrangement fees of £Nil (2023 - £95,541) are being released over five years from the 17 October 2019.

There is a new arrangement for the cash interest charged on both loan A and B from quarter to December 2024. Cash interest on loans due are not payable but accrued to carry forward until the termination of the loans. Total cash interest accrued of £552,716 at the year end.

Initial Vendor loan is £3,300,000 and annual interest is capitalised at a rate of 8% from the date of issue until redemption. Redemption is on the earlier of the refinancing of the Beechbrook loan or a change in control of the company. The Vendor loan's treatment has been based on the repayable date of the Beechbrook loan facilities. The total balance at the year-end including capitalised interest was £4,684,318 (2023 - £4,408,586). The amount owed to the director, included in the balance, is £90,592 (2023 - £155,136). It was agreed to repay the director £25,000 per quarter from September 2022.

14. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.12.24 31.12.23
value: £    £   
1 Ordinary £1 1 1

15. RESERVES
Retained
earnings
£   

At 1 January 2024 (15,413,537 )
Deficit for the year (3,007,027 )
At 31 December 2024 (18,420,564 )

16. ULTIMATE PARENT COMPANY

Access Fertility Topco Limited is regarded by the directors as being the company's ultimate parent company.

Access Fertility Topco Limited Group prepares consolidated financial statements and are publicly available at Companies House.

17. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is Beechbrook Capital LLP.